Imo-8400 (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 50 | 皮膚筋炎／多発性筋炎 | 4 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2015-003277-15-SE (EUCTR) | 12/04/2017 | 22/06/2016 | A Phase 2 Study of IMO-8400 in Patients with Dermatomyositis | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients with Dermatomyositis | Dermatomyositis MedDRA version: 19.1;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: IMO-8400 Product Code: IMO-8400 INN or Proposed INN: IMO-8400 Product Name: IMO-8400 Product Code: IMO-8400 INN or Proposed INN: IMO-8400 | Idera Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 36 | Phase 2 | United States;Hungary;Czech Republic;United Kingdom;Sweden | ||
| 2 | EUCTR2015-003277-15-GB (EUCTR) | 02/09/2016 | 31/12/2015 | A Phase 2 Study of IMO-8400 in Patients with Dermatomyositis | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients with Dermatomyositis | Dermatomyositis MedDRA version: 19.1;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Idera Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 36 | Phase 2 | United States;Hungary;Czech Republic;United Kingdom;Sweden | |||
| 3 | EUCTR2015-003277-15-HU (EUCTR) | 12/08/2016 | 20/06/2016 | A Phase 2 Study of IMO-8400 in Patients with Dermatomyositis | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients with Dermatomyositis | Dermatomyositis MedDRA version: 19.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: IMO-8400 Product Code: IMO-8400 INN or Proposed INN: IMO-8400 | Idera Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 36 | Phase 2 | United States;Czech Republic;Hungary;United Kingdom;Sweden | ||
| 4 | NCT02612857 (ClinicalTrials.gov) | November 2015 | 18/11/2015 | Trial of IMO-8400 in Adult Patients With Dermatomyositis | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis | Dermatomyositis | Drug: IMO-8400 Dose Group 1;Drug: IMO-8400 Dose Group 2;Drug: Placebo | Idera Pharmaceuticals, Inc. | NULL | Completed | 18 Years | 75 Years | All | 30 | Phase 2 | United States;Hungary;United Kingdom |